Evolent Health (NYSE:EVH) Lowered to “Sector Weight” Rating by KeyCorp

KeyCorp cut shares of Evolent Health (NYSE:EVH) from an overweight rating to a sector weight rating in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports.

EVH has been the topic of a number of other reports. Zacks Research upgraded shares of Evolent Health from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Oppenheimer dropped their target price on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 12th. Citigroup decreased their price target on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating for the company in a research note on Friday, January 9th. BMO Capital Markets began coverage on Evolent Health in a report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 price target for the company. Finally, Stephens raised Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 target price for the company in a research report on Thursday, November 13th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.42.

Evolent Health Price Performance

Evolent Health stock opened at $3.13 on Wednesday. Evolent Health has a 12-month low of $2.50 and a 12-month high of $12.06. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25. The firm has a 50-day moving average price of $3.52 and a 200-day moving average price of $5.85. The firm has a market capitalization of $349.42 million, a PE ratio of -0.61 and a beta of 0.27.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Tuesday, February 24th. The technology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The company had revenue of $468.72 million for the quarter, compared to analyst estimates of $468.48 million. During the same period in the prior year, the company posted ($0.02) EPS. The firm’s revenue for the quarter was down 27.5% on a year-over-year basis. As a group, equities research analysts forecast that Evolent Health will post 0.08 EPS for the current year.

Institutional Trading of Evolent Health

Several large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its position in Evolent Health by 88.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after acquiring an additional 1,194 shares during the period. CIBC Private Wealth Group LLC lifted its stake in Evolent Health by 4,000.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the period. Strs Ohio purchased a new stake in shares of Evolent Health in the 1st quarter valued at $47,000. Headlands Technologies LLC acquired a new stake in shares of Evolent Health in the second quarter worth $58,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in Evolent Health in the third quarter valued at $51,000.

More Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 results beat on EPS and showed operational highlights — Evolent reported $0.08 EPS vs. consensus $0.06 and revenue roughly in line (~$468.7M). Management highlighted strong oncology growth, customer renewals and migration to enhanced contract models, which investors view as evidence of improving unit economics and product traction. Earnings Call Transcript
• Positive Sentiment: FY‑2026 revenue guidance was set near $2.4–$2.6B, roughly in line with consensus, suggesting stable forward revenue expectations after a challenging prior year. That guidance underpins the upbeat market reaction despite mixed signals elsewhere. Press Release
• Positive Sentiment: Certain sell‑side firms kept buy ratings even after lowering targets — Needham cut its PT to $4 but stayed at Buy, and BTIG trimmed its PT to $8 while remaining Buy. Those continued buy calls likely provided support to the rally. Analyst Notes
• Neutral Sentiment: Analysts and articles parsed key metrics and estimates — coverage notes the quarter beat modestly on EPS and was essentially in line on revenue; some commentary focuses on how key metrics compare to Street expectations. Zacks Analysis
• Negative Sentiment: Multiple analyst downgrades and target cuts raise near‑term skepticism — KeyCorp downgraded EVH from Overweight to Sector Weight, and RBC lowered its PT to $3 with a Sector Perform rating. Those moves signal concern about valuation and near‑term growth risks. Analyst Actions
• Negative Sentiment: Underlying revenue trends remain a caution — FY revenue was down ~27.5% YoY in the quarter and margins remain pressured (negative net margin), which supports some analysts’ lower targets and explains continued volatility. Earnings Snapshot

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.